EP Patent

EP3955934A1 — Injectable triamcinolone formulations

Assigned to Clearside Biomedical Inc · Expires 2022-02-23 · 4y expired

What this patent protects

The present disclosure relates to pharmaceutical suspensions of triamcinolone acetonide, methods of producing such suspensions and methods of using of such suspensions. The pharmaceutical suspensions of the present disclosure are stable and suitable for administration by supracho…

USPTO Abstract

The present disclosure relates to pharmaceutical suspensions of triamcinolone acetonide, methods of producing such suspensions and methods of using of such suspensions. The pharmaceutical suspensions of the present disclosure are stable and suitable for administration by suprachoroidal injection through a 30-gauge microneedle.

Drugs covered by this patent

Patent Metadata

Patent number
EP3955934A1
Jurisdiction
EP
Classification
—
Expires
2022-02-23
Drug substance claim
No
Drug product claim
No
Assignee
Clearside Biomedical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.